Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$56.81 – $98.58
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.45B | $17.94B | $18.54B | $19.43B | $22.58B | $24.50B | $27.03B | $27.82B |
| Cost of revenue | $5.38B | $5.79B | $5.93B | $6.11B | $7.05B | $8.17B | $8.76B | $9.72B |
| Gross profit | $11.07B | $12.15B | $12.61B | $13.31B | $15.53B | $16.33B | $18.27B | $18.10B |
| Gross margin | 67.3% | 67.7% | 68.0% | 68.5% | 68.8% | 66.6% | 67.6% | 65.1% |
| R&D | $640.0M | $692.0M | $708.0M | $755.0M | $866.0M | $872.0M | $913.0M | $898.3M |
| Operating income | $5.09B | $5.16B | $5.85B | $6.36B | $6.44B | $6.77B | $7.32B | $7.57B |
| EBITDA | $5.65B | $5.68B | $6.35B | $7.05B | $7.23B | $7.73B | $8.48B | $8.32B |
| Net income | $3.85B | $3.87B | $4.20B | $4.83B | $4.71B | $4.78B | $5.05B | $3.63B |
| Net margin | 23.4% | 21.6% | 22.6% | 24.8% | 20.8% | 19.5% | 18.7% | 13.0% |
| EPS (diluted) | 18.10 | 18.17 | 19.68 | 22.63 | 22.11 | 22.19 | 22.46 | 16.10 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $28.6B | $24.79 | $22.64–$29.36 | 11 |
| 2027 | $30.5B | $26.44 | $26.09–$26.69 | 8 |
| 2028 | $32.5B | $28.63 | $28.25–$28.91 | 10 |
| 2029 | $34.8B | $32.35 | $31.92–$32.66 | 4 |
Forward consensus · source: Financial Modeling Prep
COLOPLAST B ORD
No one on the platform currently holds CLPBF.
No tracked institution reports a position in CLPBF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-19 | $5.0000 | 2026-05-20 |
| 2025-12-08 | $18.0000 | 2025-12-09 |
| 2025-05-09 | $5.0000 | 2025-05-12 |
| 2024-12-09 | $17.0000 | 2024-12-10 |
| 2024-05-13 | $5.0000 | 2024-05-15 |
| 2023-12-08 | $16.0000 | 2023-12-12 |
| Execution date | Ratio |
|---|---|
| 2004-12-16 | 2-for-1 |
No one on the platform has traded CLPBF yet.
| $21.0B |
| — |
| SBHMYSino Biopharmaceutical Limited | $12.68 | +0.00% | $11.3B | — |
| SDMHFSartorius Stedim Biotech S.A. | $200.02 | -1.90% | $19.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 2.8× earnings vs its 5.7× historical median P/E.
Fair value ≈ $114.78 · price $56.90 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.